Eisenmenger Complex Management Market Snapshot (2023 to 2033)
The global Eisenmenger complex managementmarket is expected to surpass an impressive valuation of US$ 7.7 Billion in 2023 and is projected to reach US$ 12.9 Billion by 2033,trailing at a CAGR of 5.3%
The increase in the number of patients suffering from mild congenital heart diseases and the growing focus on research and development activities related to the development of advanced drugs are factors anticipated to drive the growth of the global Eisenmenger syndrome treatment market. About 1 in 4 babies with congenital heart diseases have critical CHDs. Infants with the critical disease generally need surgery or other procedures in their first year of life.
Rising investment by major players for the development of innovative solutions and high spending on healthcare infrastructure development are factors anticipated to create new prospects for players operating in the Eisenmenger syndrome treatment market over the forecast period. In addition, growing partnership and agreements between players in order to improve the business presence is expected to support the revenue growth of the target market.
Report Attribute
Details
Expected Market Value (2023)
US$ 7.7Billion
Anticipated Forecast Value (2033)
US$ 12.9 Billion
Projected Growth Rate (2023 to 2033)
CAGR 5.3%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Eisenmenger Complex Management Demand Analysis vs. Forecast 2023 to 2033
The market for Eisenmenger complex treatment market was worth US$ 6.2 Billion in 2018, growing at a CAGR of 4.52% during the historical period. Continuous requirement of medication supports the growth of the Eisenmenger Syndrome Treatment Market.
Eisenmenger Syndrome is a chronic disease and requires medication to be taken for a long period of time. The incidence and prevalence of Eisenmenger syndrome have not been properly defined due to the highly specific nature of the condition. However, according to National Center for Biotechnology Information (NCBI), 2010, an estimated 8% of patients with congenital heart disease are expected to develop Eisenmenger syndrome. Though technological and healthcare advancements have made it possible to correct congenital heart defects, the responses have been poor in the case of patients suffering from Eisenmenger syndrome.
Also, the presence of disease-targeting therapies such as Sildenafil and Bosentan is expected to boost market growth during the forecast period, due to the unavailability of alternative options. Furthermore, combination therapies are also expected to boost market growth over the forecast period. After a comprehensive analysis of the above-mentioned growth factors, the market for Eisenmenger syndrome treatment is projected to grow at a 5.3% CAGR while reaching a market valuation of USD 12.9 billion by end of the forecast period.
Which are Some Prominent Drivers of the Eisenmenger Complex Management Market?
Increasing clinical trials for product development to drive market growth
Major players are investing highly in developing products such as blood thinning agents and endothelin receptor antagonists in order to treat the problems. Increasing clinical trials related to the development of new products is expected to augment the growth of the target market. In 2021, The USA. Food and Drug Administration approved “Pradaxa” a blood thinning agent. The approval of Pradaxa is expected to help pediatric patients have another therapeutic option to treat and prevent potentially deadly blood clots.
The presence of disease-targeting therapies such as Sildenafil and Bosentan has boosted the market growth over the past years and the trend is expected to remain the same, owing to the unavailability of alternative options. Moreover, combination therapies are also expected to boost the growth of the market over the forecast period. European Society of Cardiology Consensus Guidelines, 2015, suggests the use of combination therapy (Sildenafil + Bosentan, and others) in the management of pulmonary hypertension. These factors are expected to boost the growth of the market over the forecast period.
The government of developed and developing countries is spending high on the development of the healthcare sector. Their approach towards providing advanced care to patients along with better diagnostic facilities is gaining traction. Diagnosis tests such as blood tests, electrocardiograms (ECG), and chest X-rays are gaining attraction among consumers. Awareness related to these testing is increasing and is widely adopted by consumers.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Projected to be Faced by the Market?
High costs of equipment and dearth of infrastructure restraining growth
Factors such as a lack of developed infrastructure and complex regulations by the government for product approval are anticipated to restrain the growth of the global Eisenmenger syndrome treatment market. In addition, the high cost associated with the development of equipment is expected to challenge the growth of this market.
Region-Wise Insights
What is the growth outlook in North America?
North America dominates the market with a significant market share
The market in North America is expected to account for 48.7% market share with a CAGR of 5.1% during the forecast period. The growth is attributable to a high patient pool suffering from chronic diseases. The presence of many players operating in the country and introducing new solutions are factors expected to augment the regional market growth. In addition, increasing acquisition activities by major players in order to enhance the business and enhance the customer base is expected to support the growth of the Eisenmenger syndrome treatment market.
What are the growth prospects in South Asia?
South Asia will propel growth by witnessing the fastest CAGR
The market in South Asia is expected to witness the fastest compound annual growth rate of 5.5 % during the forecast period. Factors responsible for growth in this region are increasing government spending on the healthcare sector, favorable business policies by the government, and the emergence of small and mid-size players with enhanced solutions. These factors are expected to support the growth of Eisenmenger's complex management market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category wise Insights
By drug type, which segment will possess the maximum share?
Endothelin receptor antagonist to account for the dominant share
This segment is anticipated to dominate the market while capturing a 48.1% segment share in 2023. It is estimated to reflect a CAGR of 6.1% during the forecast period. The growth is attributed to favorable long-term and short-term outcomes in trials with orally active dual endothelin receptor antagonist bosentan in patients with Eisenmenger's syndrome. Furthermore, the safety and efficacy of these drugs in correcting the Eisenmenger syndrome are also driving the growth of this segment. Furthermore, increasing adoption of Endothelin receptor antagonist as a targeted therapy to dilate blood vessels, delay the progression of pulmonary arterial hypertension, and reverse the damage to the lungs and heart are set to fuel this segment over the forthcoming years.
Which is the leading distribution channel in Eisenmenger complex management market?
Hospital pharmacies rule the market with the maximum share
In terms of distribution channels, the hospital pharmacies segment is projected to remain at the forefront in the assessment period. It is estimated to account for a market share of 65% by end of the forecast period. The growth is attributable to the increasing patient visits to hospitals for the treatment of Eisenmenger syndrome.
In addition, the increasing sales of prescribed drugs for the treatment of this disorder from hospital pharmacies are anticipated to support the growth of this segment. Besides, many government agencies are likely to set up awareness campaigns in hospitals to educate the general public about this condition and the drugs available for treatment. This factor is also expected to boost the growth of this segment in the near future.
Start-ups in Eisenmenger Complex Management Market
Founded in 2015, Morphogen-IX is a Cambridge, United Kingdom-based start-up that is developing a new treatment for pulmonary arterial hypertension (PAH). Its leading candidate can directly target the major pathway implicated in human genetic studies (BMP9 and BMP10) which are small molecule-based receptors. This company was granted funding of USD 25.3 million from Medicxi, Cambridge Innovation Capital, Index Ventures, Cambridge Enterprise, and 2 others. The latest funding round was held in December 2018.
Founded in 2012, ‘1 Drop diagnostics’ is a Neuchatel, Switzerland-based start-up that provides finger-prick point-of-care diagnostic solutions. The proprietary technology uses a combination of lab-on-chip microfluidic technology that enables biomarker testing to occur using very small volumes of blood, and advanced photonics to easily detect fluorescence due to the immunoassays. The first application is cardiovascular health, using biomarkers such as NT-proBNP, D-Dimer, Troponin, and C-reactive protein. It was granted funding of USD 8 million from Christian Wildmoser, Hans-Peter Strebel, Beat Schillig, and 9 Other Investors.
Market Competition
The global Eisenmenger syndrome treatment market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are Actelion Pharmaceuticals Ltd, Gilead Sciences, Inc., Pfizer, Inc, Teva Pharmaceutical Industries Ltd, AstraZeneca plc., Novartis AG, Merck and Co., Inc., GlaxoSmithKline plc., Mylan N.V, Bayer AG.
Some recent developments in this industry are:
In July 2022, Cereno Scientific announced that the first patient had been enrolled in the Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1.
In June 2022, Gossamer Bio, Inc. declared the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH).
In December 2021, Aerovate Therapeutics, a clinical-stage biopharmaceutical company based in the United States, started the Phase 2b/3 clinical trial for testing imatinib, its experimental inhaled formulation in people with Eisenmenger syndrome. The trial is set to help the company in achieving the goal of enhancing the lives of patients suffering from rare cardiovascular diseases. This test will evaluate the ability of AV-101 to resist blood flow in the blood vessels of the lungs.
In December 2021, Alembic Pharmaceuticals, a multinational pharmaceutical company headquartered in India, bagged approval from the United States Food and Drug Administration (USFDA) for the marketing of Selexipag December 2021, Alembic Pharmaceuticals tablets. These can now be used to treat pulmonary arterial hypertension. The company’s new drug is considered to be the generic equivalent to Uptravi, the Reference Listed Drug (RLD).
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 7.7 Billion
Market Value in 2033
US$ 12.9 Billion
Growth Rate
CAGR of 5.3% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD billion and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
By drug
By diagnosis
By distribution channel
By end-user
By Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)
Key Countries Profiled
USA
Canada
Brazil
Mexico
Germany
UK
France
Spain
Italy
India
China
Japan
Malaysia
Singapore
Thailand
South Korea
Australia
New Zealand
UAE
South Africa
Israel
GCC countries
Key Companies Profiled
Actelion Pharmaceuticals Ltd
Gilead Sciences, Inc.
Pfizer, Inc
Teva Pharmaceutical Industries Ltd
AstraZeneca plc.
Novartis AG
Merck and Co., Inc.
GlaxoSmithKline plc.
Mylan N.V
Bayer AG
Customization
Available Upon Request
Key Segments Profiled in the Eisenmenger Complex Management Industry Survey
By Drug Type:
Antiarrhythmic Agents
Blood Thinning Agents
Endothelin Receptor Antagonist
Others
By Diagnosis:
Blood tests
Electrocardiogram
Chest X-ray
Echocardiogram
CT Scan
MRI
Cardiac Catheterization
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By End User:
Hospitals & Clinics
Laboratories
Others
By Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa (MEA)
Frequently Asked Questions
How is the Historical Performance of the Market?
From 2018 to 2022, the market registered a CAGR of 4.52%.
How Big will the Eisenmenger Complex Management Market by 2033?
The market is estimated to be worth US$ 12.9 million by 2033.
Which Drug Type Holds Lucrative Opportunities?
Antiarrhythmic agents hold high revenue potential.
Which Countries Dominate the Global Market?
The United States, India, and China dominate the global market.
What is the Growth Forecast for the Eisenmenger Complex Management Market?
The market is forecast to register a CAGR of 5.3% through 2033.
Table of Content
1. Executive Summary | Eisenmenger Complex Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033
5.3.1. Antiarrhythmic Agents
5.3.2. Blood Thinning Agents
5.3.3. Endothelin Receptor Antagonist
5.3.4. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Diagnosis, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Diagnosis, 2023 to 2033
6.3.1. Blood tests
6.3.2. Electrocardiogram
6.3.3. Chest X-ray
6.3.4. Echocardiogram
6.3.5. CT Scan
6.3.6. MRI
6.3.7. Cardiac Catheterization
6.4. Y-o-Y Growth Trend Analysis By Diagnosis, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Diagnosis, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Online Pharmacies
7.3.3. Retail Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-user
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2023 to 2033
8.3.1. Hospitals & Clinics
8.3.2. Laboratories
8.3.3. Others
8.4. Y-o-Y Growth Trend Analysis By End-user, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By End-user, 2023 to 2033
9. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East & Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. USA
10.2.1.2. Canada
10.2.2. By Drug Type
10.2.3. By Diagnosis
10.2.4. By Distribution Channel
10.2.5. By End-user
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Diagnosis
10.3.4. By Distribution Channel
10.3.5. By End-user
10.4. Key Takeaways
11. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Type
11.2.3. By Diagnosis
11.2.4. By Distribution Channel
11.2.5. By End-user
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Diagnosis
11.3.4. By Distribution Channel
11.3.5. By End-user
11.4. Key Takeaways
12. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. UK
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Type
12.2.3. By Diagnosis
12.2.4. By Distribution Channel
12.2.5. By End-user
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Diagnosis
12.3.4. By Distribution Channel
12.3.5. By End-user
12.4. Key Takeaways
13. South Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Drug Type
13.2.3. By Diagnosis
13.2.4. By Distribution Channel
13.2.5. By End-user
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Diagnosis
13.3.4. By Distribution Channel
13.3.5. By End-user
13.4. Key Takeaways
14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Type
14.2.3. By Diagnosis
14.2.4. By Distribution Channel
14.2.5. By End-user
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Type
14.3.3. By Diagnosis
14.3.4. By Distribution Channel
14.3.5. By End-user
14.4. Key Takeaways
15. Oceania Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Drug Type
15.2.3. By Diagnosis
15.2.4. By Distribution Channel
15.2.5. By End-user
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Type
15.3.3. By Diagnosis
15.3.4. By Distribution Channel
15.3.5. By End-user
15.4. Key Takeaways
16. Middle East & Africa Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of Middle East & Africa
16.2.2. By Drug Type
16.2.3. By Diagnosis
16.2.4. By Distribution Channel
16.2.5. By End-user
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Type
16.3.3. By Diagnosis
16.3.4. By Distribution Channel
16.3.5. By End-user
16.4. Key Takeaways
17. Key Countries Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Type
17.1.2.2. By Diagnosis
17.1.2.3. By Distribution Channel
17.1.2.4. By End-user
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Type
17.2.2.2. By Diagnosis
17.2.2.3. By Distribution Channel
17.2.2.4. By End-user
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Type
17.3.2.2. By Diagnosis
17.3.2.3. By Distribution Channel
17.3.2.4. By End-user
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Type
17.4.2.2. By Diagnosis
17.4.2.3. By Distribution Channel
17.4.2.4. By End-user
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Type
17.5.2.2. By Diagnosis
17.5.2.3. By Distribution Channel
17.5.2.4. By End-user
17.6. UK
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Type
17.6.2.2. By Diagnosis
17.6.2.3. By Distribution Channel
17.6.2.4. By End-user
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Type
17.7.2.2. By Diagnosis
17.7.2.3. By Distribution Channel
17.7.2.4. By End-user
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Type
17.8.2.2. By Diagnosis
17.8.2.3. By Distribution Channel
17.8.2.4. By End-user
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Type
17.9.2.2. By Diagnosis
17.9.2.3. By Distribution Channel
17.9.2.4. By End-user
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Type
17.10.2.2. By Diagnosis
17.10.2.3. By Distribution Channel
17.10.2.4. By End-user
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Type
17.11.2.2. By Diagnosis
17.11.2.3. By Distribution Channel
17.11.2.4. By End-user
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Type
17.12.2.2. By Diagnosis
17.12.2.3. By Distribution Channel
17.12.2.4. By End-user
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Type
17.13.2.2. By Diagnosis
17.13.2.3. By Distribution Channel
17.13.2.4. By End-user
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Type
17.14.2.2. By Diagnosis
17.14.2.3. By Distribution Channel
17.14.2.4. By End-user
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Type
17.15.2.2. By Diagnosis
17.15.2.3. By Distribution Channel
17.15.2.4. By End-user
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Type
17.16.2.2. By Diagnosis
17.16.2.3. By Distribution Channel
17.16.2.4. By End-user
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Type
17.17.2.2. By Diagnosis
17.17.2.3. By Distribution Channel
17.17.2.4. By End-user
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Type
17.18.2.2. By Diagnosis
17.18.2.3. By Distribution Channel
17.18.2.4. By End-user
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Type
17.19.2.2. By Diagnosis
17.19.2.3. By Distribution Channel
17.19.2.4. By End-user
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Type
17.20.2.2. By Diagnosis
17.20.2.3. By Distribution Channel
17.20.2.4. By End-user
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Drug Type
17.21.2.2. By Diagnosis
17.21.2.3. By Distribution Channel
17.21.2.4. By End-user
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Type
18.3.3. By Diagnosis
18.3.4. By Distribution Channel
18.3.5. By End-user
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Actelion Pharmaceuticals Ltd.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Gilead Sciences, Inc.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. Pfizer, Inc.
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Teva Pharmaceutical Industries Ltd.
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. AstraZeneca plc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Novartis AG
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Merck and Co., Inc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. GlaxoSmithKline plc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Mylan N.V.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Bayer AG
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
20. Assumptions & Acronyms Used21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 3: Global Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 4: Global Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 5: Global Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 6: North America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 7: North America Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 8: North America Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 9: North America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 10: North America Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 11: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 12: Latin America Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 13: Latin America Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 14: Latin America Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 15: Latin America Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 16: Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: Europe Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 18: Europe Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 19: Europe Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 20: Europe Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 21: South Asia Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: South Asia Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 23: South Asia Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 24: South Asia Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 25: South Asia Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 26: East Asia Value (US$ Million) Forecast by Country, 2018 to 2033
Table 27: East Asia Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 28: East Asia Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 29: East Asia Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 30: East Asia Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 31: Oceania Value (US$ Million) Forecast by Country, 2018 to 2033
Table 32: Oceania Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 33: Oceania Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 34: Oceania Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 35: Oceania Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 36: Middle East & Africa Value (US$ Million) Forecast by Country, 2018 to 2033
Table 37: Middle East & Africa Value (US$ Million) Forecast by Drug Type, 2018 to 2033
Table 38: Middle East & Africa Value (US$ Million) Forecast by Diagnosis, 2018 to 2033
Table 39: Middle East & Africa Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 40: Middle East & Africa Value (US$ Million) Forecast by End-user, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Value (US$ Million) by Drug Type, 2023 to 2033
Figure 2: Global Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 3: Global Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 4: Global Value (US$ Million) by End-user, 2023 to 2033
Figure 5: Global Value (US$ Million) by Region, 2023 to 2033
Figure 6: Global Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 7: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 8: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 9: Global Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 10: Global Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 11: Global Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 12: Global Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 13: Global Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 14: Global Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 15: Global Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 16: Global Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 17: Global Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 18: Global Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 19: Global Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 20: Global Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 21: Global Attractiveness by Drug Type, 2023 to 2033
Figure 22: Global Attractiveness by Diagnosis, 2023 to 2033
Figure 23: Global Attractiveness by Distribution Channel, 2023 to 2033
Figure 24: Global Attractiveness by End-user, 2023 to 2033
Figure 25: Global Attractiveness by Region, 2023 to 2033
Figure 26: North America Value (US$ Million) by Drug Type, 2023 to 2033
Figure 27: North America Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 28: North America Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 29: North America Value (US$ Million) by End-user, 2023 to 2033
Figure 30: North America Value (US$ Million) by Country, 2023 to 2033
Figure 31: North America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 32: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 33: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 34: North America Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 35: North America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 36: North America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 37: North America Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 38: North America Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 39: North America Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 40: North America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 41: North America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 42: North America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 43: North America Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 44: North America Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 45: North America Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 46: North America Attractiveness by Drug Type, 2023 to 2033
Figure 47: North America Attractiveness by Diagnosis, 2023 to 2033
Figure 48: North America Attractiveness by Distribution Channel, 2023 to 2033
Figure 49: North America Attractiveness by End-user, 2023 to 2033
Figure 50: North America Attractiveness by Country, 2023 to 2033
Figure 51: Latin America Value (US$ Million) by Drug Type, 2023 to 2033
Figure 52: Latin America Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 53: Latin America Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 54: Latin America Value (US$ Million) by End-user, 2023 to 2033
Figure 55: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 56: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 57: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 58: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 59: Latin America Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 60: Latin America Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 61: Latin America Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 62: Latin America Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 63: Latin America Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 64: Latin America Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 65: Latin America Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 66: Latin America Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 67: Latin America Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 68: Latin America Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 69: Latin America Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 70: Latin America Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 71: Latin America Attractiveness by Drug Type, 2023 to 2033
Figure 72: Latin America Attractiveness by Diagnosis, 2023 to 2033
Figure 73: Latin America Attractiveness by Distribution Channel, 2023 to 2033
Figure 74: Latin America Attractiveness by End-user, 2023 to 2033
Figure 75: Latin America Attractiveness by Country, 2023 to 2033
Figure 76: Europe Value (US$ Million) by Drug Type, 2023 to 2033
Figure 77: Europe Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 78: Europe Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 79: Europe Value (US$ Million) by End-user, 2023 to 2033
Figure 80: Europe Value (US$ Million) by Country, 2023 to 2033
Figure 81: Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 82: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 83: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 84: Europe Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 85: Europe Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 86: Europe Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 87: Europe Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 88: Europe Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 89: Europe Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 90: Europe Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 91: Europe Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 92: Europe Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 93: Europe Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 94: Europe Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 95: Europe Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 96: Europe Attractiveness by Drug Type, 2023 to 2033
Figure 97: Europe Attractiveness by Diagnosis, 2023 to 2033
Figure 98: Europe Attractiveness by Distribution Channel, 2023 to 2033
Figure 99: Europe Attractiveness by End-user, 2023 to 2033
Figure 100: Europe Attractiveness by Country, 2023 to 2033
Figure 101: South Asia Value (US$ Million) by Drug Type, 2023 to 2033
Figure 102: South Asia Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 103: South Asia Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 104: South Asia Value (US$ Million) by End-user, 2023 to 2033
Figure 105: South Asia Value (US$ Million) by Country, 2023 to 2033
Figure 106: South Asia Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 107: South Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 108: South Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 109: South Asia Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 110: South Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 111: South Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 112: South Asia Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 113: South Asia Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 114: South Asia Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 115: South Asia Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 116: South Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 117: South Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 118: South Asia Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 119: South Asia Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 120: South Asia Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 121: South Asia Attractiveness by Drug Type, 2023 to 2033
Figure 122: South Asia Attractiveness by Diagnosis, 2023 to 2033
Figure 123: South Asia Attractiveness by Distribution Channel, 2023 to 2033
Figure 124: South Asia Attractiveness by End-user, 2023 to 2033
Figure 125: South Asia Attractiveness by Country, 2023 to 2033
Figure 126: East Asia Value (US$ Million) by Drug Type, 2023 to 2033
Figure 127: East Asia Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 128: East Asia Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 129: East Asia Value (US$ Million) by End-user, 2023 to 2033
Figure 130: East Asia Value (US$ Million) by Country, 2023 to 2033
Figure 131: East Asia Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 132: East Asia Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 133: East Asia Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 134: East Asia Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 135: East Asia Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 136: East Asia Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 137: East Asia Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 138: East Asia Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 139: East Asia Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 140: East Asia Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 141: East Asia Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 142: East Asia Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 143: East Asia Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 144: East Asia Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 145: East Asia Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 146: East Asia Attractiveness by Drug Type, 2023 to 2033
Figure 147: East Asia Attractiveness by Diagnosis, 2023 to 2033
Figure 148: East Asia Attractiveness by Distribution Channel, 2023 to 2033
Figure 149: East Asia Attractiveness by End-user, 2023 to 2033
Figure 150: East Asia Attractiveness by Country, 2023 to 2033
Figure 151: Oceania Value (US$ Million) by Drug Type, 2023 to 2033
Figure 152: Oceania Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 153: Oceania Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 154: Oceania Value (US$ Million) by End-user, 2023 to 2033
Figure 155: Oceania Value (US$ Million) by Country, 2023 to 2033
Figure 156: Oceania Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 157: Oceania Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 158: Oceania Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 159: Oceania Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 160: Oceania Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 161: Oceania Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 162: Oceania Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 163: Oceania Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 164: Oceania Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 165: Oceania Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 166: Oceania Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 167: Oceania Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 168: Oceania Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 169: Oceania Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 170: Oceania Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 171: Oceania Attractiveness by Drug Type, 2023 to 2033
Figure 172: Oceania Attractiveness by Diagnosis, 2023 to 2033
Figure 173: Oceania Attractiveness by Distribution Channel, 2023 to 2033
Figure 174: Oceania Attractiveness by End-user, 2023 to 2033
Figure 175: Oceania Attractiveness by Country, 2023 to 2033
Figure 176: Middle East & Africa Value (US$ Million) by Drug Type, 2023 to 2033
Figure 177: Middle East & Africa Value (US$ Million) by Diagnosis, 2023 to 2033
Figure 178: Middle East & Africa Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 179: Middle East & Africa Value (US$ Million) by End-user, 2023 to 2033
Figure 180: Middle East & Africa Value (US$ Million) by Country, 2023 to 2033
Figure 181: Middle East & Africa Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 182: Middle East & Africa Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 183: Middle East & Africa Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 184: Middle East & Africa Value (US$ Million) Analysis by Drug Type, 2018 to 2033
Figure 185: Middle East & Africa Value Share (%) and BPS Analysis by Drug Type, 2023 to 2033
Figure 186: Middle East & Africa Y-o-Y Growth (%) Projections by Drug Type, 2023 to 2033
Figure 187: Middle East & Africa Value (US$ Million) Analysis by Diagnosis, 2018 to 2033
Figure 188: Middle East & Africa Value Share (%) and BPS Analysis by Diagnosis, 2023 to 2033
Figure 189: Middle East & Africa Y-o-Y Growth (%) Projections by Diagnosis, 2023 to 2033
Figure 190: Middle East & Africa Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 191: Middle East & Africa Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 192: Middle East & Africa Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 193: Middle East & Africa Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 194: Middle East & Africa Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 195: Middle East & Africa Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 196: Middle East & Africa Attractiveness by Drug Type, 2023 to 2033
Figure 197: Middle East & Africa Attractiveness by Diagnosis, 2023 to 2033
Figure 198: Middle East & Africa Attractiveness by Distribution Channel, 2023 to 2033
Figure 199: Middle East & Africa Attractiveness by End-user, 2023 to 2033
Figure 200: Middle East & Africa Attractiveness by Country, 2023 to 2033
